How could the lawsuit challenging the CMS pricing model affect Medicare?
The GLOBE model challenge could alter Medicare Part B drug pricing and rebates. The lawsuit filed by PhRMA challenges the Global Benchmark for Efficient Drug Pricing (GLOBE) model, which CMS uses for Medicare Part B. This model is a 'most favored nation' (MFN) policy that requires drugmakers to pay rebates if their prices exceed those in 19 comparable countries, including Canada, Germany, Japan, and the United Kingdom. If the court declares GLOBE unlawful and vacates the rule, the specific international benchmark pricing framework used by Medicare Part B would be removed, forcing the program to revert to its previous domestic rebate calculation methods. This change would directly impact how drug costs are calculated and reimbursed under Medicare.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Over the long term
- The story
- No new developments lately
How it reaches Medicare
-
The Pharmaceutical Research and Manufacturers of America filed a lawsuit in the US District Court for the District of Columbia challenging the CMS Global Benchmark for Efficient Drug Pricing (GLOBE) model. This model, a 'most favored nation' pricing policy for Medicare Part B, uses international benchmarks from 19 countries to calculate manufacturer rebates. The lawsuit asks the court to declare the rule unlawful and vacate it entirely.
The full event2independent outlets -
GLOBE is a mandatory pricing policy for Medicare Part B, which covers therapies given in health care settings. If the court rules against CMS, the GLOBE model would be declared unlawful and vacated, thereby removing the international benchmark pricing structure that CMS uses to calculate rebates and limit drug prices within the Medicare Part B program.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
US federal health insurance
Everything about Medicare
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- GLOBE is a 'most favored nation' (MFN) pricing policy for Medicare Part B.ajmc.com
- The model uses reference prices from 19 countries, including Canada, Germany, Japan, and the United Kingdom.ajmc.com, medicaldaily.com
- Participation is mandatory for manufacturers of eligible drugs with annual Medicare spending above $100 million.ajmc.com
- The model is set to begin January 1, 2027.ajmc.com, medicaldaily.com
Why it matters
The core stake is the future of drug pricing within Medicare. CMS implemented GLOBE to lower out-of-pocket costs for beneficiaries and reduce overall Medicare spending, arguing that Americans pay significantly more for brand-name drugs than in other developed countries. If the model survives the legal challenge, it could lead to reduced coinsurance for about 25% of Original Medicare Part B beneficiaries in selected areas, starting April 1, 2027.
If the lawsuit succeeds, the entire pricing structure for Medicare Part B would be thrown into legal uncertainty, potentially reverting to the previous domestic rebate framework. This would fundamentally change how drug manufacturers are required to price their products and how Medicare calculates its federal reimbursement rates.
What we don't know yet
- What specific legal grounds will the court use to rule on the constitutionality of the GLOBE model?
- If the model is vacated, what specific pricing mechanism will Medicare revert to?
Is this still moving?
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
What would change this answer
— Other considerations
Beyond this explainer
Explore connected ideas
Each opens a map of what the web connects to it, with Brind's news on it.
The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.
Who else could feel it
Other possible ripples from the same event.
- JapanPossibleThe lawsuit could remove the mandatory use of Japanese benchmark pricing for Medicare drugs.
- Department of Health & Human ServicesPossibleLegal challenge to CMS pricing model creates regulatory uncertainty for HHS
- HumanaPossibleHumana may face disruption to risk models if CMS drug pricing is overturned
Reporting
- ajmc.comThursday
- medicaldaily.comThursday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.